HAEM5:Myelodysplastic/myeloproliferative neoplasm, NOS: Difference between revisions
| [unchecked revision] | [unchecked revision] |
Bailey.Glen (talk | contribs) No edit summary |
Bailey.Glen (talk | contribs) No edit summary |
||
| Line 4: | Line 4: | ||
{{Under Construction}} | {{Under Construction}} | ||
<blockquote class='blockedit'>{{Box-round|title=HAEM5 Conversion Notes|This page was converted to the new template on 2023- | <blockquote class='blockedit'>{{Box-round|title=HAEM5 Conversion Notes|This page was converted to the new template on 2023-12-04. The original page can be found at [[HAEM4:Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN), Unclassifiable]]. | ||
}}</blockquote> | }}</blockquote> | ||
==Primary Author(s)*== | ==Primary Author(s)*== | ||
| Line 38: | Line 38: | ||
When an underlying MPN has not been identified, the category of MDS/MPN-U is appropriate. <ref name=":0" /> | When an underlying MPN has not been identified, the category of MDS/MPN-U is appropriate. <ref name=":0" /> | ||
Cases with features of MDS/MPN-U may arise due to prior exposure to treatment and are included in the [[ | Cases with features of MDS/MPN-U may arise due to prior exposure to treatment and are included in the [[HAEM5:Myeloid neoplasm post cytotoxic therapy|Therapy-related myeloid neoplasms]] (t-MN). | ||
Well-defined MPN which subsequently develop dysplastic features and progress to a more aggressive phase are excluded from this category. | Well-defined MPN which subsequently develop dysplastic features and progress to a more aggressive phase are excluded from this category. | ||
| Line 78: | Line 78: | ||
<blockquote class='blockedit'>{{Box-round|title=v4:Clinical Features|The content below was from the old template. Please incorporate above.}} | <blockquote class='blockedit'>{{Box-round|title=v4:Clinical Features|The content below was from the old template. Please incorporate above.}} | ||
*Overlap with [[Myelodysplastic Syndromes (MDS)|MDS]] and [[Myeloproliferative Neoplasms (MPN)|MPN]] <ref name=":0" /> | *Overlap with [[HAEM4:Myelodysplastic Syndromes (MDS)|MDS]] and [[HAEM4:Myeloproliferative Neoplasms (MPN)|MPN]] <ref name=":0" /> | ||
*Clinically the most heterogeneous of the MDS/MPN <ref name=":3" /> | *Clinically the most heterogeneous of the MDS/MPN <ref name=":3" /> | ||
*Does not have features that define it as belonging to any of the other categories of MDS/MPN <ref name=":0" /><ref name=":1" /> | *Does not have features that define it as belonging to any of the other categories of MDS/MPN <ref name=":0" /><ref name=":1" /> | ||
| Line 130: | Line 130: | ||
<blockquote class='blockedit'>{{Box-round|title=v4:Immunophenotype|The content below was from the old template. Please incorporate above.}} | <blockquote class='blockedit'>{{Box-round|title=v4:Immunophenotype|The content below was from the old template. Please incorporate above.}} | ||
May be similar to that of [[Myelodysplastic Syndromes (MDS)|MDS]] or [[Myeloproliferative Neoplasms (MPN)|MPN]] <ref name=":0" /> | May be similar to that of [[HAEM4:Myelodysplastic Syndromes (MDS)|MDS]] or [[HAEM4:Myeloproliferative Neoplasms (MPN)|MPN]] <ref name=":0" /> | ||
</blockquote> | </blockquote> | ||